The global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.
Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction.
The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.
According to the report, improvement in diagnostic technologies is a key driver aiding to the growth of this market. There has been an increase in research activities involved in the development of various diagnostic tools for cystic fibrosis. For instance, scientists at Stanford University have developed a DNA test for the accurate and comprehensive screening of newborns for cystic fibrosis. This test utilizes the next-generation DNA sequencing which can identify the entire CFTR gene rather than just looking at selected mutations. This is considered to be less expensive and less time-consuming technology, which will contribute to this market's growth in the coming years.